

Access Research Careers [MARC]; and 93.375, Minority Biomedical Research Support [MBRS])

Dated: January 31, 1997.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 97-3078 Filed 2-6-97; 8:45 am]

BILLING CODE 4140-01-M

Office of Extramural Research; Notice of Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Peer Review Oversight Group (PROG) on February 13-14, 1997, in the Rockledge II Centre, 6701 Rockledge Drive, Bethesda, Maryland 20817. The meeting will be held from 8:30 a.m. to 5 p.m. on February 13 and from 8:30 a.m. to 12 p.m. on February 14. The meeting is open to the public, with attendance limited to space available.

Topics for discussion include: NIH extramural electronic reinvention activities, the rating of grant applications, the integration of Neuroscience Reviews, and the review of multiple mechanisms within one review group.

The meeting agenda and roster of committee members are available on the World Wide Web via the NIH Home Page (<http://www.nih.gov.grants/>) or from Dr. Peggy McCardle, Executive Secretary, PROG, and Special Assistant to the Deputy Director for Extramural Research, OD, NIH, Building 1, Room 150, Bethesda, Maryland 20892, (301) 402-2246. Individuals who plan to attend the meeting and need special assistance, such as sign language interpretation or other special accommodations, should contact Dr. McCardle by February 7, 1997.

This meeting is being published less than 15 days prior to the meeting due to the urgent need to proceed with the meeting as scheduled in order to address these issues in a timely manner.

Dated: January 31, 1997.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 97-3079 Filed 2-6-97; 8:45 am]

BILLING CODE 4140-01-M

Prospective Grant of Exclusive License: Particle-Medicated Gene Delivery DNA Vaccines Against Dengue and Other Flavivirus Infections

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a limited field of use exclusive world-wide license to practice the invention embodied in U.S. Patent No. 5,494,671, issued February 27, 1996 (U.S. Patent Application Serial No. 07/747,785, filed August 20, 1991), entitled "C-Terminally Truncated Dengue and Japanese Encephalitis Virus Envelope Proteins"; U.S. Patent Application Serial No. 08/250,802, filed May 27, 1994, entitled "Chimeric and/or Growth Restricted Flaviviruses" and related foreign patent applications to Auragen, Inc./Geniva, Inc. of Middleton, WI. The patent rights in these inventions have been assigned to the United States of America.

SUPPLEMENTARY INFORMATION: The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. It is anticipated that this license may be limited to particle-mediated gene delivery DNA vaccines against Dengue and other flavivirus infections. This license will not include live virus, killed virus, or protein-based vaccines. This prospective exclusive license may be granted unless within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The patent describes the use of C-terminally truncated flavivirus envelope proteins in vaccines against flavivirus infections and also relates to recombinant viruses which encode the truncated protein. The patent applications are directed to recombinant, modified or viable chimeric flaviviruses for use in vaccine preparations against flavivirus infections. This technology further provides for a baculovirus having a recombinant dengue cDNA sequence which encodes dengue proteins and for a baculovirus having a recombinant Japanese B encephalitis virus cDNA sequence which encodes Japanese B encephalitis proteins. The applications also relate to vaccines produced from recombinant DNA.

ADDRESSES: Requests for a copy of the issued patent, patent application, inquiries, comments, and other materials relating to the contemplated license should be directed to: Gloria H. Richmond, Patent Advisor, Office of Technology Transfer, National Institutes

of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 496-7057 ext 268; Facsimile: (301) 402-0220; E-mail: Gloria.Richmond@NIH.GOV. A signed Confidential Disclosure Agreement will be required to receive a copy of the patent application. Applications for a non-exclusive or exclusive license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by NIH on or before April 8, 1997 will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: January 28, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 97-3080 Filed 2-6-97; 8:45 am]

BILLING CODE 4140-01-M

Prospective Grant of Exclusive License: Vaccines for Dengue and Other Flaviviruses

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a limited field of use exclusive world-wide license to practice the invention embodied in U.S. Patent No. 5,494,671, issued February 27, 1996 (U.S. Patent Application Serial No. 07/747,785, filed August 20, 1991), entitled "C-Terminally Truncated Dengue and Japanese Encephalitis Virus Envelope Proteins" to Hawaii Biotechnology Group, Inc. of Aiea, Hawaii. The patent rights in this invention have been assigned to the United States of America.

SUPPLEMENTARY INFORMATION: The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. It is anticipated that this license may be limited to the field of subunit vaccines against Dengue and Japanese Encephalitis produced in animal cells. This license will not include live virus, killed virus or DNA-based vaccines or the use of vaccinia virus as a vector, or immunogen. This prospective exclusive license may be granted unless within 60 days from the